drugset / Trial / NCT06293950
Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
NaSingle-groupOpen-labelTreatment
Summary
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.
Timeline
- Start
- 2022-03-09
- Primary completion
- 2026-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Wharton Jelly Mesenchymal Stromal Cell | Unknown | 1e+06 cells/kg | Intravenous |